Leon-nanodrugs GmbH (LEON), a pharmatech firm specializing within the improvement of nanoencapsulation techniques for genetic materials and different energetic substances, introduced right now the closing of a Sequence D financing spherical. New lead investor LBBW Enterprise Capital closed the spherical along with new traders and present shareholders like Albany Personal Fairness Holdings Pty Ltd., CD-Enterprise GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Companions, TVM Life Science Innovation I L.P., and others.
“I’m very happy that we’ve accomplished this financing within the deliberate quantity. The brand new funds will probably be used to enhance the product portfolio. Our portfolio of main gear is designed to serve the Cell & Gene Remedy trade, enabling extremely financial GMP manufacturing of small and individualized batches of nanoencapsulated Cell & Gene Therapies. Along with the financing, this places us in an excellent place to pick the absolute best strategic associate to deliver these merchandise to the market”, commented Christian Nafe, Managing Director & CFO of LEON.
LEON’s strongly differentiated techniques supply vital USP’s filling present trade gaps:
- NANOscreen: bench-top system for simplified formulation screening
- NANOlab®: bench-top system for quick and environment friendly course of improvement
- NANOme® : aseptic manufacturing system for prime throughput small- and individualized scale
- GMP manufacturing requiring no cleansing and sterilization as a result of a single use element
- NANOus® : giant scale manufacturing unit for business, sterile GMP batches.
The underlying FR-JET® reactor expertise is ready for future versatility of service materials, and is optimized for minimal batch losses, and no scaling out. It’s included in all NANO-systems permitting to seamlessly scale up from course of improvement to business manufacturing.
Dr. Frank Mühlenbeck, representing lead investor LBBW Enterprise Capital, will be part of LEON’s Supervisory Board. He acknowledged: “LEON’s merchandise enable the environment friendly improvement and manufacturing of latest, upcoming modalities within the biopharma trade together with LNP’s with a particular concentrate on decentralized patient-specific remedies. Along with this bench-to-bedside strategy, LEON’s merchandise additionally empower CDMOs providing centralized manufacturing of such remedies. We utterly perceive the trade want for next-generation manufacturing options and are glad to help LEON of their effort to advance their merchandise to commercialization.”
Dr. Hubert Birner, Managing Associate at TVM Life Science Administration and Chairman of LEON’s Supervisory Board acknowledged: “As a long-standing investor in LEON, we welcome the funding of LBBW VC, because it comes at a pivotal time for LEON to facilitate use of our lead merchandise available in the market. Whereas drugs of right now embraces increasingly Cell & Gene Therapies, a wise resolution for cost-efficient, quick and but dependable and protected manufacturing remains to be required.”